Generally, doctors prescribe cancer patients with the same amount of a chemotherapy drug, but this can lead to under- or over-dosing individual patients, as each will respond differently.
As part of an Innovate UK-funded project, Physiomics has developed a tool that, from a simple blood test, could provide clinicians with a prediction of both toxicity and efficacy for any given dose.
They could then use this information to tailor the treatment to individual patients. This could potentially reduce the costs and morbidity associated with over-dosing, while it could also improve efficacy as a result of under-dosing.
Physiomics has said today it is exploring the approval of the tool as a medical device, although this would likely require further clinical validation before it could be commercialised.
But bosses pointed out that the tool could be used earlier in research settings, “thus creating the possibility of nearer term revenue potential”.
In support of the tool’s possible commercialisation, the AIM company is approaching potential strategic partners, clinical collaborators and grant providers to help it progress this “exciting opportunity”.
It has already presented a poster on the project at this year’s American Association for Cancer Research, which helped to drum up interest, while it has also spoken with the Oxford Academic Health Sciences Network and the National Institute for Health Research signposting service.
Physiomics cautioned that there is no guarantee this project will progress, although they will make an announcement later in the year should anything come of its discussions.